← Human Trials & Peer-Reviewed Studies
Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
Plain-language guide to PMID 15904630 (2005): double-blind randomized controlled trial of Angiotensin-Converting Enzyme Inhibitors in 348 patients.
Key Facts
- PMID
- 15904630
- Journal
- The American journal of cardiology
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Chaitman BR et al. (10 authors)
- DOI
- 10.1016/j.amjcard.2005.01.069
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Angiotensin-Converting Enzyme Inhibitors.
The primary objective was to compare maximum duration of exercise at peak plasma concentrations.
Why It Was Studied
A randomized, double-blind, placebo controlled parallel study evaluated omapatrilat, an inhibitor of angiotensin-converting enzyme and neutral endopeptidase.
Safety data were collected and reported for all patients.
Who Took Part
According to the abstract, 348 patients were involved.
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
Random assignment meant chance, not the researchers, decided who got Angiotensin-Converting Enzyme Inhibitors and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Angiotensin-Converting Enzyme Inhibitors, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Angiotensin-Converting Enzyme Inhibitors could be set against what happens without it.
Groups ran in parallel: each of the patients stayed in one arm throughout.
What Was Measured
A randomized, double-blind, placebo controlled parallel study evaluated omapatrilat, an inhibitor of angiotensin-converting enzyme and neutral endopeptidase.
Topics PubMed links to this paper include Angina Pectoris, Angiotensin II, Angiotensin III, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Agents, Chronic Disease and Exercise Tolerance.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin-Converting Enzyme Inhibitors in 348 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2005 (The American journal of cardiology), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.